MK-2866 (GTx-024) 化学構造
分子量: 389.33

品質と確認

Quality Control & MSDS

製品情報

  • Compare Androgen Receptor Inhibitors
    Androgen Receptor阻害剤を比較
  • 研究分野

製品の説明

生物活性

情報 MK-2866 (GTx-024)は、口で生物が利用可能な非ステロイド性の選択的なアンドロゲン受容体モジュレータ(SARM)で、 Ki が3.8 nMになる。
目標 Androgen receptor (AR)
IC50 3.8 nM (Ki) [1]
In vitro試験 Ostarine at the concentration of 10 nM modulates the transcriptional activity of AR in CV-1 cells cotransfected with a human AR expression vector, a luciferase reporter vector, and a control β-galactosidase vector, with 94%-100% relative activity of the transcriptional activation observed for 1 nM DHT. [1] [2]
In vivo試験 After intravenous administration of Ostarine at a single dose of 10 mg/kg, plasma concentration of Ostarine declines slowly, exhibiting a longer terminal half-life of 6.0 hours, as compared to that of other related cyano/nitro group-substituted SARMs with terminal halflives of 2.6-4.0 hours. Ostarine exhibits significantly androgenic and anabolic activity by stimulating the growth of prostate, seminal vesicles, and levator ani muscle when administered in castrated male rats; Ostarine is more potent than other cyano/nitro group-substituted SARMs. Ostarine restores the weight of the prostate to 39.2%, and seminal vesicle 78.8%, and stimulates the growth of levator ani muscle to a greater extent of 141.9% as compared with that of androgenic organs. Ostarine exhibits the highest in vivo androgenic and anabolic activity of any AR nonsteroidal agonist examined to date, with ED50 values of 0.12, 0.39 and 0.03 mg/day in prostate, seminal vesicles, and levator ani muscle, respectively, being 4 times as potent as testosterone propionate (TP) in levator ani muscle. At low dose of 0.03 mg/day, Ostarine is sufficient to exert efficacious and selective activity in anabolic tissues. [1]
臨床試験 Currently under Phase III study to determine if the investigational drug Ostarine can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.
特集 The most potent and tissue-selective in vivo activity of SARMs to date, with favorable pharmacokinetic properties.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

In vitro competitive radioligand binding assay The AR binding affinity of Ostarine is determined using an in vitro competitive radioligand binding assay with [3H]mibolerone (MIB). Briefly, increasing concentrations (0.01-5000 nM) of Ostarine are incubated with rat cytosol, a saturating concentration of [3H]-MIB (1 nM), and 1000 nM triamcinolone acetonide to prevent interaction of MIB with progesterone receptors at 4 °C for 18 hours. At the end of incubation, free and bound [3H]-MIB are separated using the hydroxyapatite method. IC50 value is determined by computer-fitting the data for each ligand by nonlinear regression analysi

動物実験: [1]

動物モデル Immature castrated male Sprague-Dawley rats
製剤 Dissolved in DMSO, and diluted in saline
投薬量 1 mg/day
管理 Subcutaneous injection
Solubility 1% DMSO/30% polyethylene glycol/1% Tween 80 5 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download MK-2866 (GTx-024) SDF
分子量 389.33
化学式

C19H14F3N3O3

CAS No. 841205-47-8
保管 2年-20℃
6月-80℃in DMSO
別名 Enobosarm
溶解度 (25°C) * In vitro DMSO 78 mg/mL (200.34 mM)
<1 mg/mL (<1 mM)
エタノール 78 mg/mL (200.34 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 5 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide

研究分野

製品表彰状 (2)

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related Androgen受容体 化学物質

  • Enzalutamide (MDV3100)

    Enzalutamide (MDV3100)は、36nMのIC50をもつアンドロゲン受容体(AR)敵対者です。

  • Bicalutamide

    Bicalutamideは、0.16μMのIC50をもつアンドロゲン受容体敵対者です。

    Features:Bicalutamide 和Enzalutamide联用治疗前列腺肿瘤已经进入二期临床实验阶段。

  • ARN-509

    ARN-509 is a selective androgen receptor inhibitor with IC50 of 16 nM.

  • Flutamide

    Flutamide is an antiandrogen drug, inhibits the binding of 5α-dihydrotestosterone to androgen receptors at 1-10 μM, primarily used to treat prostate cancer.

  • Galeterone

    Galeteroneは、選択的なCYP17阻害剤とアンドロゲン受容体(AR)敵対者で、IC50 がそれぞれ 300 nM と 384 nMです。

    Features:Galeterone目前唯一一种具有三种不同机制来治疗性前列腺癌的小分子化合物。

  • Andarine

    Andarineは、4nMのKiによる選択的な非ステロイド性のアンドロゲン受容体(AR)作用薬です。

    Features:Andarine是非类固醇雄激素受体(AR)选择性兴奋剂。

  • Dehydroepiandrosterone (DHEA)

    Dehydroepiandrosterone(DHEA) is a 19-carbon endogenous natural steroid hormone.

最近見られたアイテム

Tags: MK-2866 (GTx-024)を買う | MK-2866 (GTx-024)供給者 | MK-2866 (GTx-024)を購入する | MK-2866 (GTx-024)費用 | MK-2866 (GTx-024)生産者 | オーダーMK-2866 (GTx-024) | MK-2866 (GTx-024)代理店
お問い合わせ